Skin Cancer/Melanoma
Burbage Provides Nursing Perspective on 2022 ASCO Meeting
July 01, 2022
Article
Darcy Burbage, DNP, RN, AOCN, CBCN, discusses the top takeaways from the 2022 ASCO Annual Meeting for oncology nurses.
Experts Make the Case for Buprenorphine Use in Cancer-Related Pain Management
June 28, 2022
Article
Mary Lynn McPherson, PharmD, BCPS, FAAHPM, and Amy A. Case, MD, FAAHPM, argue that buprenorphine should play a larger role in cancer-related pain management because of its unique pharmacology and consequent safety profile.
Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer Survivors
June 27, 2022
Article
Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.
Aliènne Salleroli on Starting the DEI Conversation in Oncology Nursing
June 20, 2022
Video
Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership.
Prescribing 20 mg of Mozart for Chemotherapy-Induced Nausea
June 20, 2022
Article
A Michigan State University investigator is preparing to expand on an encouraging pilot study that used a music-listening intervention to influence chemotherapy-induced nausea.
Patients Receiving PD-1/PD-L1 Inhibitor Therapy More Frequently Experience Secondary Adrenal Insufficiency
June 17, 2022
Article
A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population.
Updated PFS Data Continue to Support Nivolumab Plus Relatlimab in Advanced Melanoma
June 10, 2022
Article
Relatlimab, a human LAG-3 blocking antibody, plus nivolumab, elicited superior progression-free survival in patients with advanced melanoma compared to nivolumab alone.
Sotigalimab/Pembrolizumab Jumpstarts Immune Activity, Ignites Clinical Responses in Metastatic Melanoma
April 23, 2022
Article
The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.
Nivolumab/Ipilimumab Elicits Promising PFS in Second-Line Metastatic Melanoma
April 17, 2022
Article
An improved progression-free survival benefit was observed in patients with stage III unresectable or stage IV melanoma who received nivolumab plus ipilimumab.
FDA Follow-Up: Utilizing Relatlimab/Nivolumab in Clinical Practice for Metastatic Melanoma
March 25, 2022
Article
Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.